DE60335743D1 - Verbindungen und verfahren zur erhöhung der neurogenese - Google Patents

Verbindungen und verfahren zur erhöhung der neurogenese

Info

Publication number
DE60335743D1
DE60335743D1 DE60335743T DE60335743T DE60335743D1 DE 60335743 D1 DE60335743 D1 DE 60335743D1 DE 60335743 T DE60335743 T DE 60335743T DE 60335743 T DE60335743 T DE 60335743T DE 60335743 D1 DE60335743 D1 DE 60335743D1
Authority
DE
Germany
Prior art keywords
agents
neurogenesis
increasing
compounds
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335743T
Other languages
English (en)
Inventor
Goeran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegerstrand
Jessica Heidrich
Kristina Hellstroem
Johan Haeggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Fraemme
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Roennholm
Olof Zachrisson
Lilian Wikstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroNova AB
Original Assignee
NeuroNova AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326612&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60335743(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NeuroNova AB filed Critical NeuroNova AB
Application granted granted Critical
Publication of DE60335743D1 publication Critical patent/DE60335743D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
DE60335743T 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese Expired - Lifetime DE60335743D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42791202P 2002-11-20 2002-11-20
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis

Publications (1)

Publication Number Publication Date
DE60335743D1 true DE60335743D1 (de) 2011-02-24

Family

ID=32326612

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335743T Expired - Lifetime DE60335743D1 (de) 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese

Country Status (14)

Country Link
US (1) US20050009847A1 (de)
EP (1) EP1583541B1 (de)
JP (2) JP5420813B2 (de)
AT (1) ATE494904T1 (de)
AU (1) AU2003280117B2 (de)
CA (1) CA2506850C (de)
CY (1) CY1111386T1 (de)
DE (1) DE60335743D1 (de)
DK (1) DK1583541T3 (de)
ES (1) ES2359720T3 (de)
HK (1) HK1091112A1 (de)
PT (1) PT1583541E (de)
SI (1) SI1583541T1 (de)
WO (1) WO2004045592A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691145B2 (en) * 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
EP1430114B1 (de) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
US7368115B2 (en) * 2002-07-31 2008-05-06 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2546843C (en) * 2003-11-20 2015-01-06 Neuronova Ab Compounds and methods for increasing neurogenesis
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
ATE534664T1 (de) 2004-05-24 2011-12-15 Inst Cardiologie Montreal Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
US8475764B2 (en) 2004-05-24 2013-07-02 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
EP1619251A1 (de) 2004-07-22 2006-01-25 Prosensa B.V. Ein mRNA Spleisvariant des Doublecortin-ähnlichen Kinasegens und dessen Anwendung in Krebsdiagnosis und Krebstherapie
EP1850840A2 (de) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Neue zusammensetzungen zur vorbeugung und behandlung von neurodegenerativen und blutgerinnungserkrankungen
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006297041A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
WO2007106986A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
KR100838013B1 (ko) * 2006-06-07 2008-06-12 제일약품주식회사 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (de) * 2006-09-19 2009-06-10 Braincells, Inc. Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
CA2672524C (en) * 2006-12-14 2016-08-23 Neuronova Ab Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (de) * 2007-01-11 2009-12-02 Braincells, Inc. Neurogenese-modulation durch verwendung von modafinil
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CA2686760C (en) * 2007-05-11 2016-10-11 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
CA2694696A1 (en) * 2007-07-27 2009-02-05 Immuneregen Biosciences, Inc. Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2698992A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187929A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung eines peptids als therapeutisches mittel
JP2011509981A (ja) * 2008-01-18 2011-03-31 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック（セーエヌエルエス） 神経障害性疼痛の治療に使用される化合物
FR2926464B1 (fr) * 2008-01-18 2012-01-20 Centre Nat Rech Scient Composes utilisables pour le traitement de douleurs neuropathiques
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
GB0815315D0 (en) * 2008-08-21 2008-09-24 Univ Leiden Organ protection
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2408446T3 (pl) 2009-03-20 2020-03-31 Hg&H Pharmaceuticals (Pty) Limited Zastosowanie kompozycji farmaceutycznych zawierających mesembrenon
ES2702461T3 (es) 2009-03-20 2019-03-01 Hg&H Pharmaceuticals Pty Ltd Extracto de Sceletium y usos del mismo
CN102458399B (zh) 2009-04-30 2014-04-23 美国中西部大学 centhaquin的新制药用途
MX2011012043A (es) * 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
ES2688072T3 (es) * 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
CA2801281C (en) * 2010-06-16 2018-07-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
HUE029393T2 (en) 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013002879A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
BR112016000431A8 (pt) * 2013-07-08 2018-01-23 Univ Midwestern composições e métodos para o tratamento de distúrbios neuropsiquiátricos usando um agonista do receptor de endotelina-b
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
JP6820868B2 (ja) * 2015-06-22 2021-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 動物において神経新生を増強するための組成物及び方法
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3438249A4 (de) * 2016-03-31 2019-10-30 Ajinomoto Co., Inc. Medium für neurale stammzellen zur verbesserung der neuralen differenzierungsfähigkeit
JP7029707B2 (ja) * 2016-10-17 2022-03-04 国立大学法人 熊本大学 ｃＡＭＰの増加をメカニズムとする有機酸血症における神経障害治療薬剤
KR102026156B1 (ko) * 2018-03-16 2019-09-27 (주)메디노 신경줄기세포의 신경분화 방법
JP2021532070A (ja) * 2018-06-21 2021-11-25 ボード オブ リージェンツ オブ ザ ネバダ システム オブ ハイヤー エデュケーション オン ビハーフ オブ ザ ユニバーシティー オブ ネバダ リノ 向知性薬を用いて神経変性疾患を治療するための疾患修飾方法
WO2021011878A1 (en) * 2019-07-18 2021-01-21 Venturis Therapeutics, Inc. Method of treating parkinson's disease
JP2022104448A (ja) * 2020-12-28 2022-07-08 純一 今村 認知症治療薬
CN113121641B (zh) * 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN115869459A (zh) * 2021-09-27 2023-03-31 广州图微科创生物科技有限公司 促伤口愈合的多肽水凝胶及其制备方法与应用
CN115887619B (zh) * 2021-09-30 2024-03-26 四川大学 中脑星形胶质细胞源性神经营养因子的用途及药物组合物
WO2024030977A2 (en) * 2022-08-03 2024-02-08 Sightstream Biotherapeutics, Inc. Novel melanocortin analogs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0734251B1 (de) * 1993-12-17 2009-10-14 Novavax, Inc. Verfahren zur übertragung eines biologisch aktiven materials an eine zelle
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
DE60137414D1 (de) * 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
EP1385938A1 (de) * 2001-04-23 2004-02-04 Nsgene A/S Methode und kulturmedium zur herstellung von neuronalenzellen ausdrücken tyrosin hydroxylase

Also Published As

Publication number Publication date
JP2006514630A (ja) 2006-05-11
AU2003280117B2 (en) 2009-09-10
ES2359720T3 (es) 2011-05-26
DK1583541T3 (da) 2011-04-11
CA2506850C (en) 2014-05-13
JP5421194B2 (ja) 2014-02-19
PT1583541E (pt) 2011-04-06
HK1091112A1 (en) 2007-01-12
JP5420813B2 (ja) 2014-02-19
US20050009847A1 (en) 2005-01-13
WO2004045592A2 (en) 2004-06-03
EP1583541A2 (de) 2005-10-12
JP2010195841A (ja) 2010-09-09
SI1583541T1 (sl) 2011-08-31
EP1583541B1 (de) 2011-01-12
AU2003280117A1 (en) 2004-06-15
CY1111386T1 (el) 2015-08-05
CA2506850A1 (en) 2004-06-03
ATE494904T1 (de) 2011-01-15
WO2004045592A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE554108T1 (de) Verfahren bezüglich ldcam und crtam
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200500856A1 (ru) Новые химические соединения
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE490788T1 (de) Antivirale phosphonate analoge
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EA200601871A1 (ru) Способы лечения аутоиммунных и воспалительных заболеваний
DE60334839D1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
DE602005010258D1 (de) Behandlung von ballastwasser
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
DE60323533D1 (de) Methode zur stimulierung von haarwuchs auf der basis von benzopyranen